Table 4.
Results from 4 studies Investigating Gastrointestinal Microbiota Taxa and Antibodies
| Author (Year) | Patients Controls |
Material & Procedure | Results | p-value | Other |
|---|---|---|---|---|---|
| Michalsen (2005) [18] |
21 FMS 9 RA |
Faeces Culture |
No differences | n.s | pre- vs post-fasting |
|
14 FMS 7 RA |
Faeces Culture |
No differences | n.s | pre- vs post-MedDiet | |
| Goebel (2008) [19] | 33 FMS17 CRPS 57 HC |
Serum antibodies YersiniaorCampylobacter |
FMS 27% positive CRPS 13% HC Not tested |
NR | Trend for seropositivity assoc. with IP (Table 4) |
| Minerbi (2019) [27] |
77 FMS 11 FC 20 HM 48 UC |
Faeces 16S rRNA gene (V5-V6 region) / metagenome |
↓ Faecalibacterium and Bacteroides, ↑ Intestinimonas, Flavonifractor, Butyricoccus Eisenbergiella and Enterobacter. | < 0.01 |
Non-significant differences in sample diversity Variance FMS vs UC |
| Clos-Garcia (2019) [26] |
105 FMS 54 HC |
Faeces 16S rDNA microbiome(V3–V4 region) |
FMS: Absent families: Bifidobacteriaceae and Bacteroidales↑ Dorea, Roseburia, Alistipes, Papillibacter, Subdoligranulum↓ Bacteroides, Bifidobacterium, Eubacterium, Clostridium | All p ≤ 0.05 | Controls had higher diversity |
Key: n.s. not statistically significant; NR not reported; FMS Fibromyalgia; RA rheumatoid arthritis; HC healthy controls; CRPS chronic regional pain syndrome; IP intestinal permeability; FC family controls; HM household members; UC unrelated controls.